当前经导管去肾神经术治疗高血压面临的挑战  

Current Challenges of Transcatheter Renal Denervation in the Treatment of Hypertension

作　　者：陈晓平[1] 左祥浩 叶涛 黄晶[3] 蒋雄京 CHEN Xiaoping;ZUO Xianghao;YE Tao;HUANG Jing;JIANG Xiongjing(Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China;Department of Cardiovascular Medicine,Affiliated Cardiovascular Hospital of Xiamen University,Xiamen 361006,Fujian,China;Department of Cardiovascular Medicine,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 408599,China;Department of Cardiovascular Medicine,Fuwai Hospital,Chinese Academy of Medical Sciences,Beijing 100037,China)

机构地区：[1]四川大学华西医院心脏内科,四川成都610041 [2]厦门大学附属心血管病医院心血管内科,福建厦门361006 [3]重庆医科大学附属第二医院心血管内科,重庆408599 [4]中国医学科学院阜外医院心血管内科,北京100037

出　　处：《心血管病学进展》2024年第10期870-874,共5页Advances in Cardiovascular Diseases

基　　金：国家自然科学基金科学仪器重大研制项目(32127802)。

摘　　要：随着降压疗效和安全性的循证证据累积,经导管去肾神经术(RDN)正成为高血压患者(尤其是药物难治性高血压)一种新的治疗选择。但目前该技术仍存在平均血压降幅有限、治疗应答率不高、缺乏明确的术中神经消融靶标和消融终点,以及心血管结局获益证据不足等关键问题。现系统地阐述目前RDN在高血压治疗领域面临的挑战,有助于了解RDN技术发展现状和促使该技术未来的良性发展。With the accumulation of efficacy and safety evidence,transcatheter renal denervation(RDN)is becoming an important treatment option for hypertensive patients(especially for drug uncontrolled hypertension).However,at present,this technology still faces some key obstacles,such as limited mean blood pressure reduction,a low response rate,lack of clear intraoperative nerve ablation targets and procedural endpoints,as well as insufficient evidence of cardiovascular outcomes.This review systematically summarized the current challenges of RDN in the treatment of hypertension,which may contribute to understand the development status of RDN and promoting the future improvement of this technology.

关 键 词：高血压 去肾神经术 高血压介入 肾神经刺激 

分 类 号：R544.1[医药卫生—心血管疾病]